Article Text


PTU-063 Assessment of Sleep Impairment in Patients With Crohn’S Disease: Results from the Ustekinumab Certifi Study
  1. C Gasink1,
  2. D Chan1,
  3. L-L Gao1,
  4. B Schenkel2,
  5. C Han3
  1. 1Janssen R&D, LLC
  2. 2Janssen Scientific Affairs, LLC, Spring House
  3. 3Janssen Pharmaceutical Services, Malvern, United States


Introduction To describe the extent of sleep impairment reported in CERTIFI (Ph2 evaluating UST in inducing & maintaining clinical response & remisison)using Jenkins Sleep Evaluation Questionnaire (JSEQ) & establish a clinically meaningful improvement threshold for JSEQ.

Methods Pts with moderate-to-severe CD(CDAI ≥220 & ≤450) who had previously failed or were intolerant to ≥1 anti-TNF were randomised to PBO/UST induction at wk0. Primary endpt was clinical response (≥100-pt reduction in CDAI from BL) at wk6. Sleep impairment assessed using JSEQ (total score 0–20; higher scores indicate greater sleep impairment) at BL&wk6. Relationships between BL sleep impairment, clinical disease activity (CDAI), & HRQoL impact(IBDQ) evaluated using Pearson correlation. Clinically meaningful improvement threshold of JSEQ was established with the anchor-based [clinical response by reduction in CDAI of ≥70-pt or clinically meaningful improvement (≥16-pt) in IBDQ] & distribution-based (change by one-half of the standard deviation [SD] of BL JSEQ score) methods. Prop of pts who achieved clinically meaningful improvements in JSEQ at wk6 was determined & compared.

Results At BL,both grps(n = 526) experienced similar degree of moderate sleep impairment, with JSEQ scores (mean±SD) of 11.0 ± 4.30(PBO)&11.0 ± 4.59(UST),resp. About 60% were “waking up feeling tired and worn out”; about 30–35% of pts had trouble falling asleep, staying asleep,& woke up several times during the night for 15–30 days in the previous month. At BL, JSEQ was correlated with CDAI (r = 0.19, p < 0.0001)&IBDQ(r = –0.39, p < 0.0001). Using the anchor-based method, pts who achieved vs didn’t achieve clinically meaningful improvements in CDAI or IBDQ at wk6 vs BL, reported improvements(mean±SD)from BL in JSEQ of –2.52 ± 4.43vs-0.58 ± 3.51 & –2.68 ± 4.16vs-0.16 ± 3.45, resp. Using distribution-based method, the JSEQ clinically meaningful improvement threshold was 2.25(SDof BL JSEQ = 4.50). 2 potential thresholds for clinically meaningful improvement in JSEQ (eg.reduction of > 2 or > 3 points from BL JSEQ score at wk6) were derived. More pts who received UST induction achieved both thresholds at wk6(Table).

Abstract PTU-063 Table

Conclusion Pts experience significant sleep problems as measured by JSEQ; magnitude of impairment correlates with disease activity. Both anchor- &distribution-based methods derive similar thresholds representative of clinically meaningful improvements in JSEQ. UST induction resulted in a greater proportion of pts achieving clinically meaningful improvements in sleep impairments.

Disclosure of Interest C. Gasink Employee of: Janssen R&D, LLC, D. Chan Employee of: Janssen R&D, LLC, L.-L. Gao Employee of: Janssen R&D, LLC, B. Schenkel Employee of: Janssen Scientific Affairs, LLC, C. Han Employee of: 3. Janssen Pharmaceutical Services

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.